ARCHIVES

EPO Controversy: ODAC To Review EPO Agents in May; SEC Probes Amgen’s Delay in Study Disclosure.

This article is from The Cancer Letter archive.

Vol. 33 No. 08 | March 2, 2007

Download PDF Visit The Full Archive

Related Articles

Reviewers Found For Chronobiolgy

June 30, 1989

An Alliance of NSABP-RTOG And GOG?

March 25, 2011

NCI’s Kramer Named Director, NIH Medical Applications Office.

June 16, 2000

The Emergence Of The National Dialogue On Cancer, 2000-2002: Special Report

August 8, 2003

UICC Announces Four Fellowship Program

April 22, 1983

In Brief: Patent For Semisynthetic Taxol Issued To FL Scientist; Simone To Chair Pediatric Group

June 7, 1991